An open-label, multitumor, phase II basket study of olaparib and durvalumab (MEDIOLA): results in germline BRCA-mutated (gBRCAm) HER2-negative metastatic breast cancer (MBC).
Authors
Domchek, SPostel-Vinay, S
Bang, Y
Park, Y
Alexandre, J
Delord, J
Italiano, A
You, B
Bastian, S
Krebs, Matthew G
Wang, D
Waqar, S
Angell, H
Learoyd, M
Chang, S
Gresty, C
Herbolsheimer, P
Kaufman, B
Affiliation
Cancer Research Basser Center, University of Pennsylvania, Philadelphia, PAIssue Date
2018-02-14
Metadata
Show full item recordCitation
An open-label, multitumor, phase II basket study of olaparib and durvalumab (MEDIOLA): results in germline BRCA-mutated (gBRCAm) HER2-negative metastatic breast cancer (MBC). 2018, 78(4 Suppl): PD6-11 Cancer ResJournal
Cancer ResearchDOI
10.1158/1538-7445.SABCS17-PD6-11Type
Meetings and ProceedingsLanguage
enISSN
0008-54721538-7445
ae974a485f413a2113503eed53cd6c53
10.1158/1538-7445.SABCS17-PD6-11